<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777374</url>
  </required_header>
  <id_info>
    <org_study_id>ZU-SkinSIT-003</org_study_id>
    <nct_id>NCT00777374</nct_id>
  </id_info>
  <brief_title>Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration</brief_title>
  <acronym>ZU-SkinSIT-003</acronym>
  <official_title>Single Center Phase I/IIa, Placebo Controlled, Randomized, Double-blind Preseasonal Study to Assess Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutaneous Allergen Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seasonal rhinoconjunctivitis or hay fever is a common atopic condition that is frequently&#xD;
      seen in clinical practice. Grass pollen is the major cause of pollinosis in many parts of the&#xD;
      world. Immunotherapy is the only treatment that may affect the natural course of allergic&#xD;
      diseases, and it may also prevent the development of asthma in patients with allergic&#xD;
      rhinitis. With conventional subcutaneous desensitization the duration of treatment is around&#xD;
      3-5 years and usually comprises around 30-100 allergen injections. As high allergen doses&#xD;
      have to be injected, allergic side effects may occur and patients must stay under medical&#xD;
      supervision for at least 1 hour. Transcutaneous immunization (TCI) is a needle -free&#xD;
      technique that delivers antigens and adjuvants to potent epicutaneous immune cells. The aim&#xD;
      of the new epicutaneous route of desensitization is to more specifically target the immune&#xD;
      system by loading Langerhans cells with the allergen. Lower antigen doses can be applied,&#xD;
      such that side effects are reduced.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the efficacy of the placebo patch with the allergen patch with combined symptom medication score</measure>
    <time_frame>2009 - 2011</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allergen containing patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patch</intervention_name>
    <description>epicutaneous application of allergen patch</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>epicutanoeus application of a placebo patch</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: Written informed consent History of grass pollen allergic rhinitis for&#xD;
        at least two years Male and female between 18 years to 65 years Positive skin-prick test to&#xD;
        grass pollen Positive conjunctival provocation test&#xD;
&#xD;
        Exclusion criteria: Eczematous skin lesions on the upper arms Perennial rhinitis due to&#xD;
        perennial allergies or anatomical reason (polyps, septal deviation) Symptoms of infectious&#xD;
        disease with rhinitis in between the last week Surgical intervention in between the last 30&#xD;
        days Pregnancy or nursing History of HIV or AIDS History of mastocytosis (cutaneous or&#xD;
        systemic) History of significant cardiovascular disease Uncontrolled Hypertension (blood&#xD;
        pressure &gt; 160 / 95) History of significant pulmonary, renal and/or hepatic disease History&#xD;
        of significant hematological disorder Moderate or severe asthma History of malignancy&#xD;
        Significant neurological or psychatric disease History of active autoimmune disease&#xD;
        Antihistamines with longed half-lives in the last week Systemic or topical steroids for 5&#xD;
        days Depot corticosteroids for the last two months Active infectious disease Adipositas per&#xD;
        magna&#xD;
&#xD;
        Contraindicated medications:&#xD;
&#xD;
          -  immunosuppressive agents&#xD;
&#xD;
          -  Betablockers&#xD;
&#xD;
          -  ACE-inhibitors, AT 2 Antagonists&#xD;
&#xD;
          -  tricyclic antidepressants&#xD;
&#xD;
          -  daily use of Beta-agonists or steroid inhalers&#xD;
&#xD;
          -  Participation in another clinical trial /study at the moment or within the last 60&#xD;
             days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>January 31, 2011</last_update_submitted>
  <last_update_submitted_qc>January 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Thomas KÃ¼ndig</name_title>
    <organization>University of Zurich</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

